Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CORESTEMCHEMON Inc. Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.	South Korea	166480
Corline Biomedical AB Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.	Sweden	CLBIO
CorMedix Inc. Develops a catheter lock solution to prevent bloodstream infections in hemodialysis patients.	United States of America	CRMD
Cosma Spolka Akcyjna Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.	Poland	COS
COSMO Pharmaceuticals N.V. Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.	Netherlands	COPN
Cosmos Health Inc. A global healthcare firm developing & distributing nutraceuticals, generics, and OTC medications.	United States of America	COSM
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.	United States of America	CELZ
CRESCENT BIOPHARMA, INC. A biotech company developing bispecific antibody therapies to treat solid tumors.	United States of America	CBIO
Crinetics Pharmaceuticals, Inc. Develops novel therapeutics for rare endocrine diseases and related tumors.	United States of America	CRNX
CRISPR Therapeutics AG Develops transformative CRISPR gene-based medicines for diseases like sickle cell.	United States of America	CRSP